Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week

STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that data on Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and NASP in uncontrolled gout will be presented at ASN Kidney Week 2025, 5-9...